

**EGFRVIII**  
**Catalog # PVGS1834****Specification**

---

**EGFRVIII - Product Information**

Primary Accession [NP\\_001333870.1](#)  
**Species**  
Human

**Sequence**  
Leu25-Ser378

**Purity**  
> 95% as determined by Bis-Tris PAGE  
> 95% as determined by HPLC

**Endotoxin Level**  
Less than 1EU per µg by the LAL method.

**Biological Activity**  
Immobilized EGFRVIII[Biotin], His&Avi, Human (Cat.No.: Z03941) at 0.5 µg/ml (100 µl/Well) on streptavidin (5 µg/ml) precoated plate can bind Anti-EGFR VIII Antibody, hFc Tag.

**Expression System**  
HEK293

**Theoretical Molecular Weight**  
41.6 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).**

**Reconstitution**  
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>O more than 100 µg/ml.

**Storage & Stability**  
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

**EGFRVIII - Additional Information**

**Target Background**  
Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF-α). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy.

**EGFRVIII - Protein Information**

## **EGFRVIII - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **EGFRVIII - Images**